Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells
The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidermal growth factor receptor: Mechanisms of activation and signalling
Jorissen, R. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(02)00098-8 · Cited by 1,565
pp125FAK a structurally distinctive protein-tyrosine kinase associated with focal adhesions.
Schaller, M. D., Borgman, C. A., Cobb, B. S., Vines, R. R., Reynolds, A. B., & Parsons, J. T. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.11.5192 · Cited by 1,444
Autophosphorylation of the Focal Adhesion Kinase, ppl25FAK, Directs SH2-Dependent Binding of pp60src
Schaller, M. D., Hildebrand, J. D., Shannon, J. D., Fox, J. W., Vines, R. R., & Parsons, J. T. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.3.1680-1688.1994 · Cited by 1,138
Yeatman, T. J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1366 · Cited by 1,113 · cited 1×
“Elevated Src activity has been implicated in promoting an aggressive tumour cell phenotype and thus Src presents itself as a potential therapeutic target for the prevention of tumour spread [22,28].”
BackgroundSchaller, M. D., Hildebrand, J. D., Shannon, J. D., Fox, J. W., Vines, R. R., & Parsons, J. T. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.3.1680 · Cited by 876
Src family kinases in tumor progression and metastasis
Summy, J. M., & Gallick, G. E. (2003) · Cancer and Metastasis Reviews · doi:10.1023/a:1023772912750 · Cited by 827
Src family kinases are required for integrin but not PDGFR signal transduction
Klinghoffer, R. A., Sachsenmaier, C., Cooper, J. A., & Soriano, P. (1999) · The EMBO Journal · doi:10.1093/emboj/18.9.2459 · Cited by 731
Required role of focal adhesion kinase (FAK) for integrin-stimulated cell migration
Sieg, D. J., Hauck, C. R., & Schlaepfer, D. D. (1999) · Journal of Cell Science · doi:10.1242/jcs.112.16.2677 · Cited by 687
Src in cancer: deregulation and consequences for cell behaviour
Frame, M. C. (2002) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(02)00040-9 · Cited by 683
Biscardi, J. S., Maa, M.-C., Tice, D. A., Cox, M. E., Leu, T.-H., & Parsons, S. J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.12.8335 · Cited by 649
Cited by
Triple-negative breast cancer: disease entity or title of convenience?
Carey, L., Winer, E., Viale, G., Cameron, D., & Gianni, L. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.154 · Cited by 783
Src kinases as therapeutic targets for cancer
Kim, L. C., Song, L., & Haura, E. B. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.129 · Cited by 700
Banerjee, M., Cui, X., Li, Z., Yu, H., Cai, L., Jia, X., He, D., Wang, C., Gao, T., & Xie, Z. (2018) · Scientific Reports · doi:10.1038/s41598-018-29995-2 · Cited by 506
Melatonin, a Full Service Anti-Cancer Agent: Inhibition of Initiation, Progression and Metastasis
Reiter, R., Rosales-Corral, S., Tan, D.-X., Acuna-Castroviejo, D., Qin, L., Yang, S.-F., & Xu, K. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040843 · Cited by 433
p27 Phosphorylation by Src Regulates Inhibition of Cyclin E-Cdk2
Chu, I., Sun, J., Arnaout, A., Kahn, H., Hanna, W., Narod, S., Sun, P., Tan, C.-K., Hengst, L., & Slingerland, J. (2007) · Cell · doi:10.1016/j.cell.2006.11.049 · Cited by 372
Ward, A., Balwierz, A., Zhang, J. D., Küblbeck, M., Pawitan, Y., Hielscher, T., Wiemann, S., & Sahin, Ö. (2013) · Oncogene · doi:10.1038/onc.2012.128 · Cited by 280
Pathways to tamoxifen resistance
Riggins, R. B., Schrecengost, R. S., Guerrero, M. S., & Bouton, A. H. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.03.016 · Cited by 277
Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530
Green, T. P., Fennell, M., Whittaker, R., Curwen, J., Jacobs, V., Allen, J., Logie, A., Hargreaves, J., Hickinson, D. M., Wilkinson, R. W., et al. (2009) · Molecular Oncology · doi:10.1016/j.molonc.2009.01.002 · Cited by 238
Self-citationCurrent status of SRC inhibitors in solid tumor malignancies
Puls, L. N., Eadens, M., & Messersmith, W. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0408 · Cited by 158
Dual Drug Repurposing: The Example of Saracatinib
Ramos, R., & Vale, N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084565 · Cited by 24
“The results for prostate cancer cell lines were also promising, showing a reduction in cell mobility [16,30,31].”
Background
Metadata
- Authors
- Hiscox, S., Morgan, L., Green, T. P., Barrow, D., Gee, J., & Nicholson, R. I.
- Venue
- Breast Cancer Research and Treatment
- Published
- 2005-12-07
- Volume
- 97
- Issue
- 3
- Pages
- 263-274
- ISSN
- 0167-6806 (ISSN-L)
- 1573-7217
- OpenAlex
- W2045792003
- Cited by
- 274
- References
- 51
- FWCI
- 17.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.